Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KISV: Extended Bupropion for Smoking Cessation in African Americans
NCT05732272Phase 3Recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Feb 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bupropion in nicotine dependence, sponsored by University of Kansas Medical Center. Started Feb 2023; status: recruiting.
02
Drugs
bupropion
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT05732272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732272.